EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury

Cardiovascular Research

Volumn 77, Issue 3, 2008, Pages 580-589

  Nührenberg, Thomas G ^a   Langwieser, Nicolas ^a   Schwarz, Johannes B K ^a   Hou, Yonghao ^b   Frank, Pamela ^a,e   Sorge, Falko ^a   Matschurat, Susanne ^c   Seidl, Stefan ^d   Kastrati, Adnan ^a   Schömig, Albert ^a   Clauss, Matthias A ^b   Zohlnhöfer, Dietlind ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^d Institut für Pathologie   (Germany)

^e Institut für Experimentelle Chirurgie   (Germany)

Author keywords

Adventitia; Drugs; Endothelium; Inflammation; Restenosis

Indexed keywords

ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; EVEROLIMUS; RAPAMYCIN DERIVATIVE;

ADVENTITIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; CORONARY ARTERY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATORY CELL; INTIMA; MONOCYTE; MOUSE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER;

EID: 38849088686     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvm076     Document Type: Article

References (31)

1. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002;105:2974-2980.
2. Roque M, Fallon JT, Badimon JJ, Zhang WX, Taubman MB, Reis ED. Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils. Arterioscler Thromb Vasc Biol 2000;20:335-342.
3. Sata M, Maejima Y, Adachi F, Fukino K, Saiura A, Sugiura S et al. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J Mol Cell Cardiol 2000;32:2097-2104.
4. Beohar N, Flaherty JD, Davidson CJ, Maynard RC, Robbins JD, Shah AP et al. Antirestenotic effects of a locally delivered caspase inhibitor in a balloon injury model. Circulation 2004;109:108-113.
5. Daemen MA, van' V, Denecker G, Heemskerk VH, Wolfs TG, Clauss M et al. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest 1999;104:541-549.
6. Kao J, Ryan J, Brett G, Chen J, Shen H, Fan YG et al. Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms. J Biol Chem 1992;267:20239- 20247.
7. Kao J, Fan YG, Haehnel I, Brett J, Greenberg S, Clauss M et al. A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response. J Biol Chem 1994;269:9774-9782.
8. Knies UE, Behrensdorf HA, Mitchell CA, Deutsch U, Risau W, Drexler HC et al. Regulation of endothelial monocyte-activating polypeptide II release by apoptosis. Proc Natl Acad Sci USA 1998;95:12322-12327.
9. Zohlnhöfer D, Nührenberg TG, Neumann FJ, Richter T, May AE, Schmidt R et al. Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties. Mol Pharmacol 2004;65:880-889.
10. Schwarz MA, Kandel J, Brett J, Li J, Hayward J, Schwarz RE et al. Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells. J Exp Med 1999;190:341-354.
11. Berger AC, Alexander HR, Tang G, Wu PS, Hewitt SM, Turner E et al. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. Microvasc Res 2000;60:70-80.
12. Nührenberg TG, Voisard R, Fahlisch F, Rudelius M, Braun J, Gschwend J et al. Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. FASEB J 2005;19:246-248.
13. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315- 1323.
14. Costa RA, Lansky AJ, Mintz GS, Mehran R, Tsuchiya Y, Negoita M et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol 2005;95:113-116.
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408.
16. Ziegler-Heitbrock HW, Thiel E, Futterer A, Herzog V, Wirtz A, Riethmuller G. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer 1988;41:456-461.
17. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975;51:5-40.
18. Hausleiter J, Kastrati A, Mehilli J, Vogeser M, Zohlnhöfer D, Schühlen H et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 2004;110:790-795.
19. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A. Vessel size and long-term outcome after coronary stent placement. Circulation 1998;98:1875-1880.
20. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-1115.
21. Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schömig A et al. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol 2006;48:1304-1309.
22. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-1099.
23. Shane JW, Janardhan KS, Singh B. Expression and function of endothelial monocyte-activating polypeptide-II in acute lung inflammation. Inflamm Res 2007;56:175-181.
24. Wilcox JN, Okamoto EI, Nakahara KI, Vinten-Johansen J. Perivascular responses after angioplasty which may contribute to postangioplasty restenosis: a role for circulating myofibroblast precursors? Ann NY Acad Sci 2001;947:68-90.
25. Fukuda D, Sata M, Tanaka K, Nagai R. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 2005;111:926-931.
26. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation 1998;98:224-233.
27. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-1193.
28. Farb A, John M, Acampado E, Kolodgie FD, Prescott MF, Virmani R. Oral everolimus inhibits in-stent neointimal growth. Circulation 2002;106:2379-2384.
29. Virmani R, Farb A, Guagliumi G, Kolodgie FD. Drug-eluting stents: caution and concerns for long-term outcome. Coron Artery Dis 2004;15:313-318.
30. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006;47:2108-2111.
31. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-278.